NATCO Pharma Limited (NATCOPHARM.BO)
INR 771.25
(0.63%)
INR 771.25
(0.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.81 Billion INR | -1416.06% |
| 2022 | 442 Million INR | -86.23% |
| 2021 | 3.2 Billion INR | 24.33% |
| 2020 | 2.58 Billion INR | -16.63% |
| 2019 | 3.09 Billion INR | -13.52% |
| 2018 | 3.58 Billion INR | 136.3% |
| 2017 | 1.51 Billion INR | -23.52% |
| 2016 | 1.98 Billion INR | 124.1% |
| 2015 | 884 Million INR | -71.24% |
| 2014 | 3.07 Billion INR | 32.94% |
| 2013 | 2.31 Billion INR | -29.61% |
| 2012 | 3.28 Billion INR | 82.78% |
| 2011 | 1.79 Billion INR | 8.86% |
| 2010 | 1.65 Billion INR | 48.21% |
| 2009 | 1.11 Billion INR | 14.71% |
| 2008 | 971.01 Million INR | 42.45% |
| 2007 | 681.67 Million INR | 42.73% |
| 2006 | 477.59 Million INR | -3.35% |
| 2005 | 494.15 Million INR | -23.86% |
| 2004 | 649 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 FY | -5.81 Billion INR | -1416.06% |
| 2023 Q4 | -5.81 Billion INR | -147.85% |
| 2023 Q1 | 11.62 Billion INR | 2529.19% |
| 2023 Q2 | 1.43 Billion INR | -87.65% |
| 2023 Q3 | 12.15 Billion INR | 747.11% |
| 2022 Q1 | 7.99 Billion INR | 149.27% |
| 2022 Q4 | 442 Million INR | -95.6% |
| 2022 FY | 442 Million INR | -86.23% |
| 2022 Q2 | -225 Million INR | -102.81% |
| 2022 Q3 | 10.04 Billion INR | 4564.89% |
| 2021 FY | 3.2 Billion INR | 24.33% |
| 2021 Q2 | 3.01 Billion INR | -64.75% |
| 2021 Q3 | 7.73 Billion INR | 156.62% |
| 2021 Q4 | 3.2 Billion INR | -58.5% |
| 2021 Q1 | 8.54 Billion INR | 231.19% |
| 2020 Q3 | 10.99 Billion INR | 383.34% |
| 2020 Q1 | 9.53 Billion INR | 207.98% |
| 2020 Q4 | 2.58 Billion INR | -76.53% |
| 2020 FY | 2.58 Billion INR | -16.63% |
| 2020 Q2 | 2.27 Billion INR | -76.14% |
| 2019 FY | 3.09 Billion INR | -13.52% |
| 2019 Q2 | 2.86 Billion INR | -72.9% |
| 2019 Q3 | 10.34 Billion INR | 261.03% |
| 2019 Q4 | 3.09 Billion INR | -70.08% |
| 2019 Q1 | 10.57 Billion INR | 195.42% |
| 2018 Q1 | 8.66 Billion INR | 471.82% |
| 2018 Q4 | 3.58 Billion INR | -73.76% |
| 2018 Q2 | 1.96 Billion INR | -77.28% |
| 2018 FY | 3.58 Billion INR | 136.3% |
| 2018 Q3 | 13.64 Billion INR | 593.29% |
| 2017 Q2 | 1.83 Billion INR | 170.1% |
| 2017 Q4 | 1.51 Billion INR | 8.45% |
| 2017 Q3 | 1.39 Billion INR | -23.83% |
| 2017 Q1 | 679 Million INR | -65.72% |
| 2017 FY | 1.51 Billion INR | -23.52% |
| 2016 Q2 | 1.36 Billion INR | 106.55% |
| 2016 Q1 | 660.8 Million INR | -25.25% |
| 2016 Q3 | 612.8 Million INR | -55.1% |
| 2016 FY | 1.98 Billion INR | 124.1% |
| 2016 Q4 | 1.98 Billion INR | 223.27% |
| 2015 Q2 | 358.9 Million INR | 166.25% |
| 2015 FY | 884 Million INR | -71.24% |
| 2015 Q1 | 134.8 Million INR | -95.61% |
| 2015 Q3 | 966.6 Million INR | 169.32% |
| 2015 Q4 | 884 Million INR | -8.55% |
| 2014 Q1 | 113.7 Million INR | -95.08% |
| 2014 Q2 | 2.13 Billion INR | 1774.23% |
| 2014 FY | 3.07 Billion INR | 32.94% |
| 2014 Q4 | 3.07 Billion INR | 2964.81% |
| 2014 Q3 | 100.3 Million INR | -95.29% |
| 2013 Q1 | 134.62 Million INR | -95.9% |
| 2013 Q4 | 2.31 Billion INR | 1407.36% |
| 2013 Q3 | 153.4 Million INR | -94.65% |
| 2013 FY | 2.31 Billion INR | -29.61% |
| 2013 Q2 | 2.86 Billion INR | 2031.55% |
| 2012 Q4 | 3.28 Billion INR | 1247.33% |
| 2012 FY | 3.28 Billion INR | 82.78% |
| 2012 Q2 | 2.39 Billion INR | 0.0% |
| 2012 Q3 | 243.8 Million INR | -89.82% |
| 2011 Q4 | 1.79 Billion INR | 0.0% |
| 2011 FY | 1.79 Billion INR | 8.86% |
| 2010 FY | 1.65 Billion INR | 48.21% |
| 2009 FY | 1.11 Billion INR | 14.71% |
| 2008 FY | 971.01 Million INR | 42.45% |
| 2007 FY | 681.67 Million INR | 42.73% |
| 2006 FY | 477.59 Million INR | -3.35% |
| 2005 FY | 494.15 Million INR | -23.86% |
| 2004 FY | 649 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 250.469% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 257.501% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | -104.632% |
| Granules India Limited | 9.28 Billion INR | 162.637% |
| Indoco Remedies Limited | 6.47 Billion INR | 189.82% |
| Achyut Healthcare Limited | -3.74 Million INR | -155185.638% |
| Ajanta Pharma Limited | -954.9 Million INR | -509.174% |
| Alkem Laboratories Limited | -1.6 Billion INR | -261.439% |
| Alpa Laboratories Limited | 35.36 Million INR | 16549.396% |
| Brooks Laboratories Limited | 49.48 Million INR | 11855.077% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | -16.051% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 276.329% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -402.439% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 145.048% |
| Eris Lifesciences Limited | 13.8 Billion INR | 142.133% |
| FDC Limited | -57.75 Million INR | -9972.378% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | -35.744% |
| Gufic Biosciences Limited | 3.19 Billion INR | 282.105% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | -40.066% |
| Ipca Laboratories Limited | 11.41 Billion INR | 150.958% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -318.51% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 400.943% |
| Lasa Supergenerics Limited | 205.79 Million INR | 2926.544% |
| Laurus Labs Limited | 24.38 Billion INR | 123.855% |
| Lupin Limited | 17.19 Billion INR | 133.835% |
| Mankind Pharma Limited | -9.9 Billion INR | 41.29% |
| Medicamen Biotech Limited | 160.31 Million INR | 3728.459% |
| Medico Remedies Limited | 78.67 Million INR | 7493.52% |
| Megasoft Limited | 1.28 Billion INR | 552.49% |
| Piramal Pharma Limited | 42.27 Billion INR | 113.76% |
| RPG Life Sciences Limited | -364.7 Million INR | -1495.01% |
| Sigachi Industries Limited | 859.94 Million INR | 776.435% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 91.973% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 4112.388% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 12687.912% |
| Unichem Laboratories Limited | 931.91 Million INR | 724.198% |
| Wanbury Limited | 1.1 Billion INR | 626.009% |
| Windlas Biotech Limited | -273.04 Million INR | -2030.457% |
| ZIM Laboratories Limited | 983.6 Million INR | 691.397% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 248.696% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -517.647% |
| Divi's Laboratories Limited | -39.77 Billion INR | 85.373% |
| Hester Biosciences Limited | 2.29 Billion INR | 353.935% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -147.743% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -2238.098% |
| Bal Pharma Limited | 1.26 Billion INR | 560.366% |
| Strides Pharma Science Limited | 23.25 Billion INR | 125.012% |
| Venus Remedies Limited | -267.7 Million INR | -2072.955% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 322.711% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 194.473% |
| Shilpa Medicare Limited | 9.06 Billion INR | 164.138% |
| Aarti Drugs Limited | 5.54 Billion INR | 204.841% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -428.194% |
| Suven Life Sciences Limited | -1.63 Billion INR | -256.281% |
| Ind-Swift Limited | 9.5 Billion INR | 161.176% |
| Valiant Laboratories Limited | -295.03 Million INR | -1871.651% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 306.189% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 158.002% |
| Themis Medicare Limited | 764.96 Million INR | 860.43% |
| Hikal Limited | 7.96 Billion INR | 173.014% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 118.275% |
| Sequent Scientific Limited | 4.17 Billion INR | 239.208% |
| Novartis India Limited | -5.89 Billion INR | 1.258% |
| Wockhardt Limited | 18.27 Billion INR | 131.839% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 121.487% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -31435.292% |
| Neuland Laboratories Limited | -214.05 Million INR | -2617.488% |
| Morepen Laboratories Limited | -231.17 Million INR | -2416.286% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 4945.925% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 696.12% |